Substance / Medication

Icatibant

Overview

Active Ingredient
icatibant
RxNorm CUI
1148138

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.
Jeon Jinyoung, Lee Yun Jeong, Lee Seok-Yong · J Clin Pharm Ther · 2019
PMID: 31290163Meta-Analysis
Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.
Grumach Anete S, Longhurst Hilary J, Aberer Werner et al. · J Allergy Clin Immunol Pract · 2019
PMID: 30170163Observational
Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M, Bork K, Martinez-Saguer I et al. · J Eur Acad Dermatol Venereol · 2019
PMID: 30176179ObservationalFull text (PMC)
Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
Toubi Elias, Kivity Shmuel, Graif Yael et al. · Isr Med Assoc J · 2018
PMID: 29629730Observational
Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet Laurence, Boccon-Gibod Isabelle, Launay David et al. · Immun Inflamm Dis · 2017
PMID: 28250922ObservationalFull text (PMC)
Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst H J, Zanichelli A, Caballero T et al. · Clin Exp Immunol · 2017
PMID: 27936514ObservationalFull text (PMC)
Icatibant Compared to Steroids and Antihistamines for ACE-Inhibitor-Induced Angioedema.
Botnaru Tudor, Robert Antony, Mottillo Salvatore · CJEM · 2017
PMID: 27189625Observational
Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice.
Zanichelli A, Maurer M, Aberer W et al. · Allergy · 2017
PMID: 27926986ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Icatibant (substance)
SNOMED CT
703834005
UMLS CUI
C0246269
RxNorm CUI
1148138

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.